Maravai LifeSciences (MRVI) announced the appointment of Bernd Brust as CEO and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William “Trey” Martin III in these roles. Maravai is neither reaffirming nor withdrawing its previously issued full-year 2025 financial guidance at this time. The company will revisit its outlook during the second-quarter earnings call in August, following a comprehensive assessment of the business by newly appointed CEO Mr. Brust. Most recently, he served as Executive Chairman, and previously as CEO, of Antylia Scientific.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- TriLink BioTechnologies, Quantoom Biosciences sign license, supply agreement
- Maravai Lifesciences Holds Annual Shareholders Meeting
- Hold Rating for Maravai Lifesciences Holdings Amid Revenue Challenges and Uncertainty in CleanCap Orders
- Maravai LifeSciences Q1 2025 Earnings Call: Growth Amid Challenges
- Optimistic Growth Outlook for Maravai Lifesciences Holdings Despite Challenges